Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration
Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource...
Legend Biotech’s Carvykti Secures FDA Approval for Expanded Use in Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that the US Food and Drug Administration...
Genmab Acquires Profound Bio for $1.8 Billion, Targeting Expanding ADC Pipeline
Denmark-based biotech Genmab A/S (NASDAQ: GMAB) has announced a significant all-cash acquisition of Sino-US biotech...
Boehringer Ingelheim to Shut Down Consanas Rehabilitation Unit in China Amid Disappointing Performance
Boehringer Ingelheim (BI), the Germany-based pharmaceutical firm, is set to close its Consanas Rehabilitation stroke...
European Commission Approves Reblozyl for First-Line Treatment of MDS-Related Anemia
The European Commission (EC) has granted Bristol Myers Squibb (BMS; NYSE: BMY) an indication extension...
Gilead Extends Collaboration with Nurix Therapeutics for Targeted Protein Degradation by Two Years
Gilead Sciences (NASDAQ: GILD) has announced a two-year extension of its 2019 collaboration with Nurix...
RemeGen Plans RMB 2.55 Billion Private Placement to Fund Innovative Drug Development
China-based RemeGen (HKG: 9995) has announced plans to raise RMB 2.55 billion (approximately USD 280.5...
AstraZeneca and Daiichi Sankyo File for FDA Approval of Datopotamab Deruxtecan in Breast Cancer
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, and its Japanese partner Daiichi Sankyo (TYO:...
Sichuan Biokin Secures NMPA Approval for Phase II Study of BL-M07D1 in Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506), based in China, has announced that it has...
Jiangsu Hengrui’s Fluzoparib Receives Breakthrough Therapy Designation for HER2-Negative Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a China-based pharmaceutical company, has announced that its...
Jiuyuan Gene’s Semaglutide Biosimilar Market Filing Accepted for Review in China
Hangzhou Jiuyuan Gene Engineering Co., Ltd., based in China, has announced that its market approval...
RemeGen Secures Fast-Track FDA Designation for Telitacicept in Sjögren’s Syndrome Treatment
China-based pharmaceutical company RemeGen (HKG: 9995) has announced that it has received fast-track designation (FTD)...
Hepalink Secures TFDA Approval for Enoxaparin Sodium Injection, Expanding Thrombosis Treatment Options in Thailand
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), based in China, has announced that it...
Sino Medical Secures Approval for Innovative Drug-Coated Stent System Targeting Intracranial Stenosis
Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced that it has...
Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval...
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...
Zai Lab Announces Positive Phase III Data for Krazati in KRASG12C-mutated NSCLC, Plans NDA Filing in China
Zai Lab (NASDAQ: ZLAB; HKG: 9688), a China-based biotech company, has announced positive Phase III...
Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis
Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has...
Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation
Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...
Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment
Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...